Drug Trial Radar · NCT05961098
A Study of RBD1016 in CHB Participants
Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 11, 2023
Primary completion
Apr 29, 2025
Study completion Oct 15, 2025
Sponsor
- Lead sponsor
- Suzhou Ribo Life Science Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, randomized, double-blind, placebo-controlled clinical study to assess the safety, efficacy, PK and immunogenicity of RBD1016 injection on NAs background treatment in CHB participants.
Conditions
- Chronic Hepatitis b
Interventions
RBD1016Drug
RBD1016 with NAs background treatment will be explored.
Primary outcomes
What the sponsor says the trial is designed to measure.
- safety: number and percentage of AEsTime frame: 24 weeks
- efficacy: the maximum decline of HBsAg levelTime frame: 24 weeks
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Prince of Wales Hospital
Hong Kong, China
Queen Mary Hospital
Hong Kong, China
Karolinska University Hospital
Stockholm, Stockholm County, Sweden
Clinical Trial Consultants AB
Uppsala, Uppsala County, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.